• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
The role of lipoprotein (a) in chronic kidney disease.脂蛋白(a)在慢性肾脏病中的作用。
J Lipid Res. 2018 Apr;59(4):577-585. doi: 10.1194/jlr.R083626. Epub 2018 Jan 29.
2
Lipoprotein(a) in renal disease.肾病中的脂蛋白(a)
Am J Kidney Dis. 1996 Jan;27(1):1-25. doi: 10.1016/s0272-6386(96)90026-8.
3
Lipoprotein(a) in chronic renal disease.慢性肾病中的脂蛋白(a)
Miner Electrolyte Metab. 1996;22(1-3):16-21.
4
Lipoprotein(a) serum levels and apolipoprotein(a) phenotypes in children with chronic renal disease.慢性肾病患儿的脂蛋白(a)血清水平及载脂蛋白(a)表型
Pediatr Res. 1993 Dec;34(6):772-6. doi: 10.1203/00006450-199312000-00015.
5
Elevated plasma lipoprotein(a) in patients with the nephrotic syndrome.肾病综合征患者血浆脂蛋白(a)升高。
Ann Intern Med. 1993 Aug 15;119(4):263-9. doi: 10.7326/0003-4819-119-4-199308150-00002.
6
Serum lipoprotein(a) concentrations and apolipoprotein(a) phenotypes in hemodialysis, chronic ambulatory peritoneal dialysis and post-transplant patients.血液透析、持续性非卧床腹膜透析及移植后患者的血清脂蛋白(a)浓度和载脂蛋白(a)表型
Ren Fail. 2002 Mar;24(2):187-95. doi: 10.1081/jdi-120004095.
7
Apolipoprotein(a) isoform-specific changes of lipoprotein(a) after kidney transplantation.肾移植后脂蛋白(a)的载脂蛋白(a)异构体特异性变化
Eur J Hum Genet. 2003 Sep;11(9):693-9. doi: 10.1038/sj.ejhg.5201016.
8
Factors associated with lipoprotein(a) in chronic kidney disease.慢性肾脏病中与脂蛋白(a)相关的因素。
Am J Kidney Dis. 2005 Jan;45(1):28-38. doi: 10.1053/j.ajkd.2004.08.043.
9
The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate.血浆脂蛋白(a)浓度与载脂蛋白(a)异构体大小的负相关并非由于脂蛋白(a)分解代谢的差异，而是由于生成速率的差异。
J Clin Invest. 1994 Jun;93(6):2758-63. doi: 10.1172/JCI117292.
10
Lipoprotein(a) Particle Production as a Determinant of Plasma Lipoprotein(a) Concentration Across Varying Apolipoprotein(a) Isoform Sizes and Background Cholesterol-Lowering Therapy.脂蛋白(a)颗粒生成作为不同载脂蛋白(a)亚型大小和背景降脂治疗时血浆脂蛋白(a)浓度的决定因素。
J Am Heart Assoc. 2019 Apr 2;8(7):e011781. doi: 10.1161/JAHA.118.011781.

引用本文的文献

1
Primary Prevention Aspirin, Lipoprotein(a), and Cardiorenal Outcomes in Chronic Kidney Disease: Chronic Renal Insufficiency Cohort.慢性肾脏病的一级预防：阿司匹林、脂蛋白(a)与心肾结局——慢性肾功能不全队列研究
JACC Adv. 2025 Aug 19;4(9):102068. doi: 10.1016/j.jacadv.2025.102068.
2
Lipoprotein(a) and coronary artery disease: The need for universal screening - A case-based review.脂蛋白(a)与冠状动脉疾病：普遍筛查的必要性——基于病例的综述
Am Heart J Plus. 2025 Jun 1;56:100560. doi: 10.1016/j.ahjo.2025.100560. eCollection 2025 Aug.
3
Why, how and in whom should we measure levels of lipoprotein(a): A review of the latest evidence and clinical implications.我们为何、如何以及对谁进行脂蛋白(a)水平检测：最新证据及临床意义综述
Diabetes Obes Metab. 2025 May 28. doi: 10.1111/dom.16469.
4
Lipoprotein(a) and panvascular disease.脂蛋白（a）与泛血管疾病。
Lipids Health Dis. 2025 May 24;24(1):186. doi: 10.1186/s12944-025-02600-y.
5
Association of Lipoprotein(a) With Major Adverse Limb Events and All-Cause Mortality Following Revascularization for Chronic Limb-Threatening Ischemia: A Substudy of the BEST-CLI Trial.脂蛋白(a)与慢性肢体威胁性缺血血运重建术后主要不良肢体事件及全因死亡率的关联：BEST-CLI试验的一项子研究
J Am Heart Assoc. 2025 Jun 3;14(11):e041177. doi: 10.1161/JAHA.125.041177. Epub 2025 May 22.
6
PCSK-9 Inhibitors Can Significantly Improve the Coronary Slow Flow Caused by Elevated Lipoprotein (a) in ST-Elevation Myocardial Infarction Patients With Chronic Kidney Disease.前蛋白转化酶枯草溶菌素9（PCSK-9）抑制剂可显著改善慢性肾脏病合并ST段抬高型心肌梗死患者因脂蛋白（a）升高所致的冠状动脉慢血流现象。
Catheter Cardiovasc Interv. 2025 Jul;106(1):396-407. doi: 10.1002/ccd.31543. Epub 2025 Apr 25.
7
Combined Treatment With Lipoprotein Apheresis and Hemodialysis in Patients With Severe Cardiovascular Disease, High Lipoprotein(a) and End Stage Renal Disease.脂蛋白分离术与血液透析联合治疗重度心血管疾病、高脂蛋白(a)血症及终末期肾病患者
J Clin Apher. 2025 Apr;40(2):e70020. doi: 10.1002/jca.70020.
8
Unveiling patient profiles associated with elevated Lp(a) through an unbiased clustering analysis.通过无偏聚类分析揭示与脂蛋白(a)升高相关的患者特征。
Front Cardiovasc Med. 2025 Mar 20;12:1546351. doi: 10.3389/fcvm.2025.1546351. eCollection 2025.
9
Distribution of lipoprotein (a) levels in patients with lower extremity artery disease and their impact on amputation and survival: a retrospective study.下肢动脉疾病患者脂蛋白（a）水平分布及其对截肢和生存的影响：一项回顾性研究
Lipids Health Dis. 2025 Apr 2;24(1):128. doi: 10.1186/s12944-025-02542-5.
10
Lipoprotein(a) levels and cardiovascular mortality risk in Chinese patients undergoing hemodialysis.接受血液透析的中国患者的脂蛋白（a）水平与心血管死亡风险
Int Urol Nephrol. 2025 Mar 24. doi: 10.1007/s11255-025-04459-5.

本文引用的文献

1
Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease.载脂蛋白 AI 模拟肽（Anacetrapib）在动脉粥样硬化性血管疾病患者中的作用。
N Engl J Med. 2017 Sep 28;377(13):1217-1227. doi: 10.1056/NEJMoa1706444. Epub 2017 Aug 28.
2
Lipoprotein(a) and Risk of Myocardial Infarction and Death in Chronic Kidney Disease: Findings From the CRIC Study (Chronic Renal Insufficiency Cohort).脂蛋白(a)与慢性肾脏病患者心肌梗死及死亡风险：慢性肾功能不全队列（CRIC）研究结果
Arterioscler Thromb Vasc Biol. 2017 Oct;37(10):1971-1978. doi: 10.1161/ATVBAHA.117.309920. Epub 2017 Aug 24.
3
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.依洛尤单抗与心血管疾病患者的临床结局。
N Engl J Med. 2017 May 4;376(18):1713-1722. doi: 10.1056/NEJMoa1615664. Epub 2017 Mar 17.
4
Phenotypic Characterization of Genetically Lowered Human Lipoprotein(a) Levels.遗传性降低的人脂蛋白(a)水平的表型特征
J Am Coll Cardiol. 2016 Dec 27;68(25):2761-2772. doi: 10.1016/j.jacc.2016.10.033.
5
Effect of extended-release niacin on plasma lipoprotein(a) levels: A systematic review and meta-analysis of randomized placebo-controlled trials.烟酸缓释剂对血浆脂蛋白(a)水平的影响：一项随机安慰剂对照试验的系统评价和荟萃分析。
Metabolism. 2016 Nov;65(11):1664-1678. doi: 10.1016/j.metabol.2016.08.007. Epub 2016 Aug 31.
6
Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology.脂蛋白（a）作为心血管疾病的一个病因：来自流行病学、遗传学和生物学的见解
J Lipid Res. 2016 Nov;57(11):1953-1975. doi: 10.1194/jlr.R071233. Epub 2016 Sep 27.
7
Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials.靶向载脂蛋白(a)的反义寡核苷酸在脂蛋白(a)升高的人群中的应用：两项随机、双盲、安慰剂对照、剂量范围试验。
Lancet. 2016 Nov 5;388(10057):2239-2253. doi: 10.1016/S0140-6736(16)31009-1. Epub 2016 Sep 21.
8
Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials.肾功能对基于他汀类药物的 LDL 胆固醇降低治疗效果的影响：来自 28 项随机试验的个体参与者数据的荟萃分析。
Lancet Diabetes Endocrinol. 2016 Oct;4(10):829-39. doi: 10.1016/S2213-8587(16)30156-5. Epub 2016 Jul 29.
9
Global Prevalence of Chronic Kidney Disease - A Systematic Review and Meta-Analysis.全球慢性肾脏病患病率——一项系统评价与荟萃分析
PLoS One. 2016 Jul 6;11(7):e0158765. doi: 10.1371/journal.pone.0158765. eCollection 2016.
10
Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences.肾病综合征中的脂质代谢紊乱：机制与后果
Kidney Int. 2016 Jul;90(1):41-52. doi: 10.1016/j.kint.2016.02.026. Epub 2016 Apr 26.

脂蛋白(a)在慢性肾脏病中的作用。

The role of lipoprotein (a) in chronic kidney disease.

机构信息

Clinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.

Clinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Medical Research Council Population Health Research Unit, Oxford, United Kingdom.

出版信息

J Lipid Res. 2018 Apr;59(4):577-585. doi: 10.1194/jlr.R083626. Epub 2018 Jan 29.

DOI:10.1194/jlr.R083626
PMID:29378781
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5880503/
Abstract

Lipoprotein (a) [Lp(a)] and its measurement, structure and function, the impact of ethnicity and environmental factors, epidemiological and genetic associations with vascular disease, and new prospects in drug development have been extensively examined throughout this Thematic Review Series on Lp(a). Studies suggest that the kidney has a role in Lp(a) catabolism, and that Lp(a) levels are increased in association with kidney disease only for people with large apo(a) isoforms. By contrast, in those patients with large protein losses, as in the nephrotic syndrome and continuous ambulatory peritoneal dialysis, Lp(a) is increased irrespective of apo(a) isoform size. Such acquired abnormalities can be reversed by kidney transplantation or remission of nephrosis. In this Thematic Review, we focus on the relationship between Lp(a), chronic kidney disease, and risk of cardiovascular events.

摘要

脂蛋白 (a)[Lp(a)]及其检测、结构与功能、种族和环境因素的影响、与血管疾病的流行病学和遗传学关联，以及药物研发的新前景，这些都是本系列关于 Lp(a) 的专题评论所广泛探讨的内容。研究表明，肾脏在 Lp(a) 的分解代谢中起作用，而且只有携带大载脂蛋白 (apo)a 异构体的人，其 Lp(a) 水平才会随着肾脏疾病的发生而升高。相比之下，在那些存在大量蛋白丢失的患者中，例如肾病综合征和持续不卧床腹膜透析患者，无论 apo(a) 异构体大小如何，Lp(a) 均会升高。这些获得性异常可通过肾移植或肾病缓解得到逆转。在本专题评论中，我们重点关注 Lp(a)、慢性肾脏病与心血管事件风险之间的关系。